We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer Aggressiveness Linked to Lack of COMMD1 Protein Activity

By LabMedica International staff writers
Posted on 14 Jun 2010
Cancer researchers have linked low levels of the COMMD1 (copper metabolism (Murr1) domain containing 1) protein to increased cancer aggressiveness and tendency to metastasize.

COMMD1 has been shown to inhibit both NF-kappaB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) and HIF (hypoxia inducible factor) mediated gene expression. More...
NF-kappaB and HIF are transcription factors that have been shown to play a role in promoting tumor growth, survival, and invasion.

In the current study, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied the role of COMMD1 expression in human cancers. They reported in the June 2010 issue of the Journal of Clinical Investigation that analysis of COMMD1 levels in 63 patients with endometrial cancer showed that those whose tumors had the lowest levels of COMMD1 had the worst clinical outcomes. Experiments in animals revealed that direct repression of the COMMD1 gene in human cell lines led to increased tumor invasion in a chick xenograft model, while increased COMMD1 gene expression in mouse melanoma cells led to decreased lung metastasis in a mouse model.

Decreased COMMD1 gene expression also correlated with increased expression of genes known to promote cancer cell invasiveness, including direct targets of HIF. At the molecular level the investigators found that COMMD1 inhibited HIF-mediated gene expression by binding directly to the amino terminus of HIF-1-alpha, preventing its dimerization with HIF-1-beta and subsequent DNA binding and transcriptional activation.

"This is the first study that clearly links COMMD1 to human disease and substantiates what we would have expected based on the prior work we have done on this protein,” said senior author Dr. Ezra Burstein, assistant professor of internal medicine and molecular biology at the University of Texas Southwestern Medical Center. "COMMD1 is yet another player in the very important and complicated cancer invasion process.”

"Further down the line we could create a drug that would bring COMMD1 protein levels back to normal, or even above normal, in the tumor to hopefully affect cancer cell invasion,” said Dr. Ezra Burstein. "If the cancer cells have already started invading other organs, maybe further invasion would be halted or even regressed.”

Related Links:

University of Texas Southwestern Medical Center




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.